Skip to main content
. 2019 Apr 17;37(16):1391–1402. doi: 10.1200/JCO.18.01460

FIG 3.

FIG 3.

Overall survival (OS) in (A) the intent-to-treat population with treatment assignments according to initial random assignment; (B) patients with either del(17p) or TP53 mutation; (C) patients with neither del(17p) nor TP53 mutation. Insets show median (95% Cl) OS for each treatment group. IDELA, idelalisib; NR, not reached; R, rituximab.